Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091778/0/en/Allarity-Therapeutics-Announces-First-Patient-Enrolled-in-New-Phase-2-Clinical-Trial-Protocol-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit

    09 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/09/3078515/0/en/Allarity-Therapeutics-Provides-First-Quarter-2025-Update-Highlighting-Continued-Stenoparib-Benefit-and-Upcoming-Trial-Enrollment.html

    GLOBENEWSWIRE
    09 May 2025
    Share Share
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3031065/0/en/Allarity-Therapeutics-to-Begin-Enrollment-for-New-Phase-2-Protocol-to-Advance-Stenoparib-Toward-FDA-Approval-in-Advanced-Ovarian-Cancer-Patients.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share
    Allarity Adds Leaders To Advance Stenoparib PARP Program
    Allarity Adds Leaders To Advance Stenoparib PARP Program

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957638/0/en/Allarity-Therapeutics-Strengthens-Leadership-with-Key-Appointments-to-Accelerate-Stenoparib-PARP-Inhibitor-Program.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer

    25 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/25/2903722/0/en/Allarity-Therapeutics-Dual-PARP-Tankyrase-Inhibitor-Stenoparib-Continues-to-Show-Extended-Clinical-Benefit-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    25 Jun 2024
    Share Share